TradeFlare's AI research teams analysed TSHA on 8 market nights between May 15, 2026 and May 27, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| May 27, 2026 | BUY | $5.59 | — / — | -3.5% | +8.0% | The stock is in a neutral market regime, and while sentiment is bullish, the technicals are neutral and the risk score is high, preventing a buy recommendation. |
| May 25, 2026 | BUY | $5.49 | $6.70 / $4.67 | +1.8% | +24.1% | The scanner signal suggests a potential short-term bounce, but the overall technical picture and high risk profile warrant caution. |
| May 22, 2026 | BUY | $5.54 | — / — | +8.7% | +24.9% | TSHA-102 Breakthrough Therapy designation for Rett syndrome. |
| May 21, 2026 | BUY | $5.49 | — / — | +6.0% | +17.9% | Positive clinical trial data for TSHA-102. |
| May 20, 2026 | HOLD | $5.18 | — / — | +7.8% | +16.9% | Positive clinical trial data for TSHA-102. |
| May 19, 2026 | BUY | $5.96 | — / — | +10.9% | +19.4% | Positive clinical trial data for lead drug candidate (TSHA-102). |
| May 18, 2026 | BUY | $5.96 | — / — | +2.7% | +7.4% | Positive clinical trial data for lead drug candidate (TSHA-102). |
| May 15, 2026 | BUY | $6.30 | — / — | -7.9% | +0.2% | Positive clinical trial data for TSHA-102. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.